Barclays’s CME Group CME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $30.3M | Buy |
102,600
+94,200
| +1,121% | +$28M | 0.01% | 930 |
|
|
2025
Q4 | $2.29M | Buy |
8,400
+5,600
| +200% | +$1.52M | ﹤0.01% | 2843 |
|
|
2025
Q3 | $757K | Sell |
2,800
-2,800
| -50% | -$762K | ﹤0.01% | 3535 |
|
|
2025
Q2 | $1.54M | Buy |
+5,600
| New | +$1.52M | ﹤0.01% | 3044 |
|
|
2024
Q1 | – | Sell |
-30,800
| Closed | -$6.49M | – | 5117 |
|
|
2023
Q4 | $6.49M | Buy |
+30,800
| New | +$6.57M | ﹤0.01% | 1876 |
|
|
2021
Q1 | – | Sell |
-3,700
| Closed | -$674K | – | 4747 |
|
|
2020
Q4 | $674K | Hold |
3,700
| – | – | ﹤0.01% | 3043 |
|
|
2020
Q3 | $619K | Hold |
3,700
| – | – | ﹤0.01% | 3073 |
|
|
2020
Q2 | $601K | Sell |
3,700
-29,300
| -89% | -$5.25M | ﹤0.01% | 3186 |
|
|
2020
Q1 | $5.71M | Buy |
33,000
+20,700
| +168% | +$4.12M | ﹤0.01% | 1366 |
|
|
2019
Q4 | $2.47M | Sell |
12,300
-14,200
| -54% | -$2.91M | ﹤0.01% | 2776 |
|
|
2019
Q3 | $5.6M | Buy |
26,500
+600
| +2% | +$125K | ﹤0.01% | 1753 |
|
|
2019
Q2 | $5.03M | Buy |
25,900
+10,800
| +72% | +$1.99M | ﹤0.01% | 1857 |
|
|
2019
Q1 | $2.48M | Sell |
15,100
-18,100
| -55% | -$3.2M | ﹤0.01% | 2342 |
|
|
2018
Q4 | $6.25M | Buy |
33,200
+12,900
| +64% | +$2.38M | ﹤0.01% | 1450 |
|
|
2018
Q3 | $3.46M | Sell |
20,300
-23,400
| -54% | -$3.94M | ﹤0.01% | 2224 |
|
|
2018
Q2 | $7.16M | Buy |
43,700
+25,300
| +138% | +$4.13M | 0.01% | 1458 |
|
|
2018
Q1 | $2.98M | Buy |
18,400
+10,600
| +136% | +$1.69M | ﹤0.01% | 2075 |
|
|
2017
Q4 | $1.14M | Sell |
7,800
-43,500
| -85% | -$6.2M | ﹤0.01% | 2991 |
|
|
2017
Q3 | $6.96M | Sell |
51,300
-32,400
| -39% | -$4.09M | 0.01% | 1296 |
|
|
2017
Q2 | $10.5M | Buy |
83,700
+71,100
| +564% | +$8.5M | 0.01% | 939 |
|
|
2017
Q1 | $1.5M | Sell |
12,600
-2,500
| -17% | -$301K | ﹤0.01% | 2354 |
|
|
2016
Q4 | $1.74M | Buy |
15,100
+4,900
| +48% | +$545K | ﹤0.01% | 2247 |
|
|
2016
Q3 | $1.07M | Buy |
10,200
+4,700
| +85% | +$491K | ﹤0.01% | 2567 |
|
|
2016
Q2 | $536K | Sell |
5,500
-31,000
| -85% | -$2.93M | ﹤0.01% | 3152 |
|
|
2016
Q1 | $3.5M | Buy |
36,500
+12,300
| +51% | +$1.12M | 0.01% | 1448 |
|
|
2015
Q4 | $2.18M | Sell |
24,200
-21,200
| -47% | -$2M | ﹤0.01% | 1960 |
|
|
2015
Q3 | $4.18M | Sell |
45,400
-5,100
| -10% | -$485K | 0.01% | 1486 |
|
|
2015
Q2 | $4.7M | Sell |
50,500
-18,700
| -27% | -$1.74M | 0.01% | 1535 |
|
|
2015
Q1 | $6.5M | Buy |
69,200
+9,400
| +16% | +$871K | 0.01% | 1361 |
|
|
2014
Q4 | $5.26M | Sell |
59,800
-9,800
| -14% | -$830K | 0.01% | 1669 |
|
|
2014
Q3 | $5.5M | Sell |
69,600
-13,400
| -16% | -$1.01M | 0.01% | 1688 |
|
|
2014
Q2 | $5.81M | Buy |
83,000
+1,200
| +1% | +$84.5K | 0.01% | 1607 |
|
|
2014
Q1 | $6.05M | Sell |
81,800
-75,500
| -48% | -$5.7M | 0.01% | 1555 |
|
|
2013
Q4 | $12.3M | Buy |
157,300
+4,900
| +3% | +$384K | 0.01% | 1105 |
|
|
2013
Q3 | $11.1M | Buy |
152,400
+75,400
| +98% | +$5.56M | 0.01% | 1070 |
|
|
2013
Q2 | $5.85M | Buy |
+77,000
| New | +$5.05M | 0.01% | 1496 |
|
Other funds holding CME
VCM
VPM
Barclays's CME Position: Q1 2026 in Review
Barclays reduced its CME Group (CME) stake by 23% in Q1 2026, selling an estimated $93.6M and leaving 1,045,739 shares worth $309M. The position accounts for 0.07% of the portfolio, ranked #199.
Barclays first reported a position in CME in Q2 2013 and has held it in 52 quarters since. The position peaked at $411M in Q3 2025. 1,790 funds tracked by Wall St. Rank hold CME as of Q1 2026.
- Barclays held 1,045,739 shares of CME Group worth $309M as of Q1 2026.
- Barclays sold 314,988 CME Group shares in Q1 2026, an estimated $93.6M.
- CME Group made up 0.07% of Barclays's portfolio in Q1 2026, its #199 holding.
- Barclays first reported a position in CME Group in Q2 2013 and has held it in 52 quarters since.
- Barclays's CME Group position peaked at $411M in Q3 2025.
- 1,790 funds tracked by Wall St. Rank held CME Group as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.